Danaher Corp

Danaher Corp Stock Forecast & Price Prediction

Live Danaher Corp Stock (DHR) Price
$247.76

17

Ratings

  • Buy 13
  • Hold 4
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$247.76

P/E Ratio

47.19

Volume Traded Today

$2.9M

Dividend

$0.27

52 Week High/low

281.70/192.35

Danaher Corp Market Cap

$180.62B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $DHR ๐Ÿ›‘

Before you buy DHR you'll want to see this list of ten stocks that have huge potential. Want to see if DHR made the cut? Enter your email below

DHR Summary

From what 17 stock analysts predict, the share price for Danaher Corp (DHR) might increase by 16.38% in the next year. This is based on a 12-month average estimation for DHR. Price targets go from $236 to $315. The majority of stock analysts believe DHR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

DHR Analyst Ratings

DHR is a stock in Healthcare which has been forecasted to be worth $288.34 as an average. On the higher end, the forecast price is $315 USD by from Keybanc and on the lower end DHR is forecasted to be $236 by from .

DHR stock forecast by analyst

These are the latest 20 analyst ratings of DHR.

Analyst/Firm

Rating

Price Target

Change

Date

Doug Schenkel
Wolfe Research

Outperform

$285

Upgrade

Oct 31, 2024
Dan Leonard
UBS

Buy

$305

Maintains

Oct 23, 2024
Catherine Schulte
Baird

Outperform

$277

Maintains

Oct 23, 2024
Daniel Arias
Stifel

Hold

$265

Maintains

Oct 23, 2024
Andrew Cooper
Raymond James

Outperform

$300

Maintains

Oct 23, 2024
Luke Sergott
Barclays

Equal-Weight

$275

Maintains

Oct 23, 2024
Paul Knight
Keybanc

Overweight

$310

Maintains

Oct 23, 2024
Dan Brennan
TD Cowen

Buy

$315

Maintains

Oct 23, 2024
Conor McNamara
RBC Capital

Outperform

$311

Maintains

Oct 23, 2024
Jacob Johnson
Stephens & Co.

Overweight

$315

Reiterates

Oct 23, 2024
Jacob Johnson
Stephens & Co.

Overweight

$315

Initiates

Oct 1, 2024
Vijay Kumar
Evercore ISI Group

Outperform

$278

Maintains

Oct 1, 2024
Conor McNamara
RBC Capital

Outperform

$300

Reiterates

Sep 6, 2024
Brandon Couillard
Wells Fargo

Equal-Weight

$280

Initiates

Aug 27, 2024

Leerink Partners

Outperform

$280

Maintains

Jul 24, 2024
Daniel Arias
Stifel

Hold

$250

Maintains

Jul 24, 2024
Luke Sergott
Barclays

Equal-Weight

$285

Maintains

Jul 24, 2024
Matthew Sykes
Goldman Sachs

Neutral

$250

Maintains

Jul 24, 2024
Catherine Schulte
Baird

Outperform

$278

Maintains

Jul 24, 2024
Conor McNamara
RBC Capital

Outperform

$300

Maintains

Jul 24, 2024

DHR Company Information

What They Do: Manufactures medical and industrial products globally.

Business Model: Danaher Corporation generates revenue through the design, manufacturing, and marketing of a wide range of professional, medical, industrial, and commercial products and services. The company operates through several segments including Biotechnology, Life Sciences, and Diagnostics, providing essential technologies and solutions for therapeutic development, laboratory automation, and clinical diagnostics.

Other Information: Danaher has established partnerships, such as a research collaboration with Stanford University's Department of Bioengineering focused on cancer drug development. Founded in 1969 and based in Washington, D.C., the company has evolved significantly since its rebranding from Diversified Mortgage Investors, Inc. in 1984.
DHR
Danaher Corp (DHR)

When did it IPO

1987

Staff Count

61,000

Country

United States

Sector/Industry

Healthcare/Diagnostics & Research

CEO

Mr. Rainer M. Blair

Market Cap

$180.62B

Danaher Corp (DHR) Financial Data

In 2023, DHR generated $23.89B in revenue, which was a decrease of -10.33% from the previous year. This can be seen as a signal that DHR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$22.28B

Revenue From 2021

$24.80B

11.30 %
From Previous Year

Revenue From 2022

$26.64B

7.42 %
From Previous Year

Revenue From 2023

$23.89B

-10.33 %
From Previous Year
  • Revenue TTM $23.74B
  • Operating Margin TTM 20.3%
  • Gross profit TTM $14.03B
  • Return on assets TTM 3.9%
  • Return on equity TTM 7.6%
  • Profit Margin 16.4%
  • Book Value Per Share 71.03%
  • Market capitalisation $180.62B
  • Revenue for 2021 $24.80B
  • Revenue for 2022 $26.64B
  • Revenue for 2023 $23.89B
  • EPS this year (TTM) $5.25

Danaher Corp (DHR) Latest News

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - Zacks Investment Research

Summary - Danaher's (DHR) international revenue trends may affect Wall Street forecasts and the future performance of its stock, suggesting potential investment considerations.

Why It Matters - Danaher's international revenue patterns influence Wall Street forecasts, affecting stock performance expectations and potential volatility in the market.

News Image

Sat, 26 Oct 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - Seven companies are generating steady profits, which are being converted into increasing passive income streams for investors.

Why It Matters - Rising passive income streams signal strong financial health and stability, making these companies attractive for long-term investment and potential capital appreciation.

News Image

Fri, 25 Oct 2024

Sentiment - POSITIVE

Source - Seeking Alpha

Summary - Danaher reported Q3 earnings with cautious optimism, indicating a return to growth. However, management refrained from providing specific forecasts, suggesting potential uncertainties ahead.

Why It Matters - Danaher's cautious Q3 earnings signal potential volatility, impacting growth forecasts and investor sentiment, indicating the need for careful assessment of future performance.

News Image

Tue, 22 Oct 2024

Sentiment - POSITIVE

Source - Reuters

Summary - Danaher exceeded Q3 profit expectations due to strong demand in diagnostics and bioprocessing, with notable growth in its molecular testing unit.

Why It Matters - Danaher's strong Q3 performance signals robust demand in key sectors, potentially driving stock price appreciation and enhancing investor confidence in the company's growth trajectory.

News Image

Tue, 22 Oct 2024

Sentiment - POSITIVE

Source - Benzinga

Summary - Danaher Corp (DHR) reported Q3 sales of $5.79 billion, a 3% increase year-over-year, surpassing the consensus estimate of $5.59 billion.

Why It Matters - Danaher Corp's stronger-than-expected sales growth signals robust demand and operational efficiency, potentially boosting investor confidence and stock performance.

News Image

Tue, 22 Oct 2024

Sentiment - NEUTRAL

Source - Seeking Alpha

Summary - Danaher Corporation (NYSE:DHR) held its Q3 2024 earnings call on October 22, 2024, with key executives discussing financial results and engaging with analysts from various institutions.

Why It Matters - Danaher's Q3 earnings call provides insights into financial performance and future guidance, influencing stock valuation and investment decisions. Analyst questions may reveal market sentiment and strategic direction.

...

DHR Frequently asked questions

The highest forecasted price for DHR is $315 from at Keybanc.

The lowest forecasted price for DHR is $236 from from

The DHR analyst ratings consensus are 13 buy ratings, 4 hold ratings, and 0 sell ratings.